XORTX Therapeutics Inc.
XRTX
$2.28
-$0.03-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -58.18% | 25.61% | |||
| Depreciation & Amortization | -29.07% | -11.34% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.37% | 17.58% | |||
| Operating Income | 42.37% | -17.58% | |||
| Income Before Tax | -109.12% | -36.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -109.12% | -36.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -109.12% | -36.92% | |||
| EBIT | 42.37% | -17.58% | |||
| EBITDA | 42.58% | -18.36% | |||
| EPS Basic | -80.00% | -28.71% | |||
| Normalized Basic EPS | -79.99% | -29.10% | |||
| EPS Diluted | -80.85% | -28.71% | |||
| Normalized Diluted EPS | -79.99% | -29.10% | |||
| Average Basic Shares Outstanding | 16.18% | 6.38% | |||
| Average Diluted Shares Outstanding | 16.18% | 6.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||